Search

Coagulation Factor IX (Recombinant)

Recombinant Coagulation Factor IX is a purified Factor IX glycoprotein produced by recombinant DNA technology. It has a primary amino acid sequence that is identical to the Ala148 allelic form of human factor IX, and has structural and f...

Gallium citrate Ga-67

Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metasta...

Sotagliflozin

Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type … [L46616] In May 2023, sotagliflozin was approved by the FDA to reduce the risk of cardiovascular death and heart failure in patients with high risk factors.[]

Aflibercept

[L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … as treatments for retinal diseases; Enzeevi (aflibercept-abzv)[L53053], approved in August 2024, was also approved by the FDA for similar indications.

Vedolizumab

[A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter. … [L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease

Aluminum acetate

Lactic acid

(From Stedman, 26th ed) Sodium lactate is the sodium salt of lactic acid, and has a mild saline taste. … Lactic acid was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]

Hydroxyurea

[A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.

N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It...

Hydromorphone

[A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]